4 biotechs to watch in 2024

A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

By Alexandra Pecci • Feb. 21, 2024

Biden or Trump: How deeply will 2024’s election outcome impact pharma?

The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.

By Michael Gibney • Feb. 20, 2024

Explore the Trendline➔

Cell and gene therapies

How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

By PharmaVoice staff

Kite’s next-gen CAR-T aims include quicker production and more disease targets

While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

By Kelly Bilodeau • Feb. 20, 2024

Value and potential of IoT and AI for chronic diseases treatment

A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024

‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

Researchers are unleashing the powers of AI for precision medicine, drug development and more.

By Alexandra Pecci • Feb. 15, 2024

The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

By Michael Gibney • Feb. 15, 2024

‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

By Michael Gibney • Feb. 14, 2024

These 4 drugs had tons of promise — and they flopped. What happened?

No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

By Alexandra Pecci • Feb. 13, 2024

3 questions hanging over the Novo-Catalent deal

As backlash builds for the recently announced matchup, critical questions remain over its impact.

By Kelly Bilodeau • Feb. 13, 2024

A new (old) mind-opening tool in the fight against Alzheimer’s disease

A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

By Kelly Bilodeau • Feb. 12, 2024

Astellas’ science chief on the leap into new technologies

After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.

By Meagan Parrish • Feb. 9, 2024

Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

By Michael Gibney • Feb. 8, 2024

Pharma has a misinformation problem — and execs could be on the hook

Investment heavyweights BlackRock and Glass Lewis want compensation clawbacks on execs who don’t protect a company’s reputation. 

By Kelly Bilodeau • Feb. 7, 2024

‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap

The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.

By Michael Gibney • Feb. 6, 2024

Government hits patent thickets on multiple fronts

Patent thickets are the latest target in lawmakers' bid to lower drug prices.

By Alexandra Pecci • Feb. 5, 2024

Could Novo, Lilly become first trillion-dollar healthcare companies?

Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

By Meagan Parrish • Feb. 2, 2024

Merck keeps deal focus with Keytruda patent cliff on horizon

The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

By Ned Pagliarulo • Feb. 1, 2024

Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?

In the first earnings call since the $43 billion Seagen deal closed, CEO Albert Bourla stressed that Pfizer is all in on the promise of ADCs to make up for COVID losses.

By Michael Gibney • Feb. 1, 2024

Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name

Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.

By Alexandra Pecci • Jan. 30, 2024

CAR-T developers respond to FDA black box warning

Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.

By Kelly Bilodeau • Jan. 30, 2024

AstraZeneca, Daiichi aim for first pan-tumor ADC approval

A “tumor agnostic” FDA approval for the companies’ Enhertu would break new ground for antibody-drug conjugates. 

By Ben Fidler • Jan. 29, 2024

‘1 plus 1 equals 3’ — the co-CEO model in pharma

Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

By Meagan Parrish • Jan. 26, 2024

The biggest questions hanging over pharma in 2024

Key trends on the horizon in the life sciences this year.

By Meagan Parrish • Jan. 25, 2024

King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

By Michael Gibney • Jan. 25, 2024

J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.

By Michael Gibney • Jan. 24, 2024